Where does OncuraKit fit in the broader liquid biopsy landscape?

The liquid biopsy market encompasses multiple analyte types: circulating tumor DNA (ctDNA) — Grail, Foundation Medicine; circulating tumor cells (CTCs) — various research platforms; cell-free RNA including miRNA — Yenos/OncuraKit; protein biomarkers — traditional PSA, CA-125, plus newer proteomics platforms; methylation — Exact Sciences Shield, Grail Galleri. OncuraKit occupies the miRNA niche within this landscape — the only commercially available amplification-free, single-molecule miRNA quantification test from urine. While ctDNA-based tests have attracted more regulatory attention (Shield has FDA approval for CRC), the miRNA-based approach has biological advantages for early detection that are supported by the published Yenos data. OncuraKit is best positioned as a proactive wellness screening tool for health-conscious adults, employers, and healthcare organizations.